Skip to main content
. 2013 Feb 6;88(2):216–221. doi: 10.4269/ajtmh.11-0812

Figure 2.

Figure 2.

Cutaneous leishmaniasis drug discovery scheme. MTA = material transfer agreement; T.I. = therapeutics initiative; i.p. = intraperitoneal; MLS = mouse leishmaniasis suppression; ID, identification; MLL = mouse leishmaniasis lesion; p.o. = per os; PK = pharmacokinetics; IVMN = in vitro micronucleus assay; hERG = human ether-à-go-go–related gene; DDI = drug-drug interaction; SAR = structure activity relationship.